Form 4: Rapport Therapeutics COO Cheryl Gault Acquires Stock Options

Cheryl Gault, Chief Operations Officer of Rapport Therapeutics, acquired stock options for 88,442 shares of common stock on June 6, 2024.

Summary

• Cheryl Gault, the Chief Operations Officer of Rapport Therapeutics, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 6, 2024, where Gault acquired stock options for 88,442 shares of Rapport Therapeutics common stock.
• The exercise price of the stock options is $17.
• These options vest over time, with 25% vesting on June 6, 2025, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a key executive is a common practice and suggests confidence in the company's future. There are no immediate negative implications.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the COO, as the options vest over a three-year period following the initial 25% vesting.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that the COO has been granted stock options, which is a common practice for aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used by companies like Amgen, Biogen, and Gilead Sciences to incentivize performance and retain key personnel.
• The vesting schedule of 25% after one year followed by monthly installments is a standard vesting arrangement, similar to those used by other companies in the sector.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the COO's interests with the company's long-term success.
• Employees may see this as a sign of stability and growth potential within the company.

Key Dates